Literature DB >> 18923745

De novo and recurrent Kaposi's Sarcoma after renal transplantation in two patients taking everolimus.

G Vergoulas, Gr Miserlis, M Leontsini, V Papanikolaou, D Takoudas.   

Abstract

Entities:  

Keywords:  Kaposi's sarcoma; ckidney transplantation; everolimus

Year:  2008        PMID： 18923745      PMCID： PMC2504405     

Source DB:  PubMed          Journal:  Hippokratia        ISSN： 1108-4189            Impact factor:   0.471


× No keyword cloud information.
  7 in total

1.  Kaposi's sarcoma in recipients of renal transplants.

Authors:  A R Harwood; D Osoba; S L Hofstader; M B Goldstein; C J Cardella; M J Holecek; R Kunynetz; R A Giammarco
Journal:  Am J Med       Date:  1979-11       Impact factor: 4.965

2.  Sirolimus for Kaposi's sarcoma in renal-transplant recipients.

Authors:  Giovanni Stallone; Antonio Schena; Barbara Infante; Salvatore Di Paolo; Antonella Loverre; Giulio Maggio; Elena Ranieri; Loreto Gesualdo; Francesco Paolo Schena; Giuseppe Grandaliano
Journal:  N Engl J Med       Date:  2005-03-31       Impact factor: 91.245

3.  No effect of sirolimus for kaposi sarcoma in a renal transplant recipient.

Authors:  Bernard Descoeudres; Olivier Giannini; Tanja Graf; Jürg Steiger; Michael Mayr
Journal:  Transplantation       Date:  2006-05-27       Impact factor: 4.939

4.  Kaposi's sarcoma and its management by radiotherapy.

Authors:  S el-Akkad; C A Bull; M A el-Senoussi; J T Griffin; M Amer
Journal:  Arch Dermatol       Date:  1986-12

Review 5.  The potential role of mTOR inhibitors in non-small cell lung cancer.

Authors:  Cesare Gridelli; Paolo Maione; Antonio Rossi
Journal:  Oncologist       Date:  2008-02

6.  Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.

Authors:  Josep M Campistol; Alex Gutierrez-Dalmau; J Vicente Torregrosa
Journal:  Transplantation       Date:  2004-03-15       Impact factor: 4.939

7.  Evaluation of susceptibility of human herpesvirus 8 to antiviral drugs by quantitative real-time PCR.

Authors:  Yan Sergerie; Guy Boivin
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.